Strategies for developing multi-epitope, subunit-based, chemically synthesized anti-malarial vaccines

Journal of Cellular and Molecular Medicine

Volumn 12, Issue 5B, 2008, Pages 1915-1935

  Patarroyo, M E ^a,b   Cifuentes, G ^a   Bermudez A ^a   Patarroyo, M A ^a,b  

^a FUNDACIÓN INSTITUTO DE INMUNOLOGÍA DE COLOMBIA FIDIC   (Colombia)

^b UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

Author keywords

Anti malarial vaccine; HLA DR 1; molecules; P. falciparum

Indexed keywords

EPITOPE; HLA DR ANTIGEN; MALARIA VACCINE; RECOMBINANT VACCINE; SUBUNIT VACCINE;

ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; GENETICS; HUMAN; IMMUNOLOGY; MALARIA; METABOLISM; PATHOGENICITY; PLASMODIUM FALCIPARUM; REVIEW; SYNTHESIS;

ANIMALS; EPITOPES; HLA-DR ANTIGENS; HUMANS; MALARIA; MALARIA VACCINES; MODELS, BIOLOGICAL; PLASMODIUM FALCIPARUM; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

PLASMODIUM FALCIPARUM;

EID: 44649194624     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00174.x     Document Type: Review

References (109)

1. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature. 2005 434 : 214 7.
2. Bozdech Z, Llinas M, Pulliam BL, Wong ED, Zhu J, DeRisi JL. The transcriptome of the intraerythrocytic developmental cycle of Plasmodium falciparum. PLoS Biol. 2003 1 : E5.
3. Le Roch KG, Zhou Y, Blair PL, Grainger M, Moch JK, Haynes JD, De La Vega P, Holder AA, Batalov S, Carucci DJ, Winzeler EA. Discovery of gene function by expression profiling of the malaria parasite life cycle. Science. 2003 301 : 1503 8.
4. Florens L, Liu X, Wang Y, Yang S, Schwartz O, Peglar M, Carucci DJ, Yates JR, 3rd., Wub Y. Proteomics approach reveals novel proteins on the surface of malaria-infected erythrocytes. Mol Biochem Parasitol. 2004 135 : 1 11.
5. Rodriguez LE, Curtidor H, Valbuena J, Puentes A, Vera-Bravo R, Urquiza M, Cifuentes G, Reyes C, Patarroyo M. Intimate molecular interactions of P. falci-parum merozoite proteins involved in invasion of red blood cells and their implications in vaccine design. Chem Rev. 2007 submitted.
6. Stubbs J, Simpson KM, Triglia T, Plouffe D, Tonkin CJ, Duraisingh MT, Maier AG, Winzeler EA, Cowman AF. Molecular mechanism for switching of P. falciparum invasion pathways into human erythrocytes. Science. 2005 309 : 1384 7.
7. Coley AM, Parisi K, Masciantonio R, Hoeck J, Casey JL, Murphy VJ, Harris KS, Batchelor AH, Anders RF, Foley M. The most polymorphic residue on Plasmodium falciparum apical membrane antigen 1 determines binding of an invasion-inhibitory antibody. Infect Immun. 2006 74 : 2628 36.
8. Carruthers VB, Blackman MJ. A new release on life: emerging concepts in pro-teolysis and parasite invasion. Mol Microbiol. 2005 55 : 1617 30.
9. Kauth CW, Woehlbier U, Kern M, Mekonnen Z, Lutz R, Mucke N, Langowski J, Bujard H. Interactions between merozoite surface proteins 1, 6, and 7 of the malaria parasite Plasmodium falciparum. J Biol Chem. 2006 281 : 31517 27.
10. Garcia JE, Puentes A, Patarroyo ME. Developmental biology of sporozoite-host interactions in Plasmodium falciparum malaria: implications for vaccine design. Clin Microbiol Rev. 2006 19 : 686 707.
11. Patarroyo ME, Romero P, Torres ML, Clavijo P, Moreno A, Martinez A, Rodriguez R, Guzman F, Cabezas E. Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature. 1987 328 : 629 22.
12. Patarroyo ME, Amador R, Clavijo P, Moreno A, Guzman F, Romero P, Tascon R, Franco A, Murillo LA, Ponton G, Trujillo G. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature. 1988 332 : 158 61.
13. Valero MV, Amador LR, Galindo C, Figueroa J, Bello MS, Murillo LA, Mora AL, Patarroyo G, Rocha CL, Rojas M, Aponte JJ, Sarmiento LE, Losada DM, Coronell CG, Ortega NN, Rosas JE, Alonso PL, Pataroyo ME. Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia. Lancet. 1993 341 : 705 10.
14. Noya O, Gabaldon Berti Y, Alarcon de, Noya B, Borges R, Zerpa N, Urbaez JD, Madonna A, Garrido E, Jimenez MA, Borges RE, Garcia P, Reyes I, Prieto W, Colmenares C, Pabon R, Barraez T, Caceres LG, Godoy N, Cifontes R. A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela. J Infect Dis. 1994 170 : 396 402.
15. Sempertegui F, Estrella B, Moscoso J, Piedrahita L, Hernandez D, Gaybor J, Naranjo P, Mancero O, Arias S, Bernal R, Cordova ME, Suarez J, Zicker F. Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an endemic area of Ecuador. Vaccine. 1994 12 : 337 42.
16. Alonso PL, Smith T, Schellenberg JR, Masanja H, Mwankusye S, Urassa H, Bastos de Azevedo I, Chongela J, Kobero S, Menendez C, Hurt N, Thomas MC, Lyimo E, Weiss NA, Hayes R, Kitua AY, Lopez MC, Kilama WL Teuscher T, Taner M. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet. 1994 344 : 1175 81.
17. Valero MV, Amador R, Aponte JJ, Narvaez A, Galindo C, Silva Y, Rosas J, Guzman F, Patarroyo ME. Evaluation of SPf66 malaria vaccine during a 22-month follow-up field trial in the Pacific coast of Colombia. Vaccine. 1996 14 : 1466 70.
18. Acosta CJ, Galindo CM, Schellenberg D, Aponte JJ, Kahigwa E, Urassa H, Schellenberg JR, Masanja H, Hayes R, Kitua AY, Lwilla F, Mshinda H, Menendez C, Tanner M, Alonso PL. Evaluation of the SPf66 vaccine for malaria control when delivered through the EPI scheme in Tanzania. Trop Med Int Health. 1999 4 : 368 96.
19. Nosten F, Luxemburger C, Kyle DE, Ballou WR, Wittes J, Wah E, Chongsuphajaisiddhi T, Gordon DM, White NJ, Sadoff JC, Heppner DG. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group. Lancet. 1996 348 : 701 7.
20. Graves P, Gelband H. Vaccines for preventing malaria (Blood stage). Cochrane Database Syst Rev. 2006 4 : CD006199.
21. Calvo M, Guzman F, Perez E, Segura CH, Molano A, Patarroyo ME. Specific interactions of synthetic peptides derived from P. falciparummerozoite proteins with human red blood cells. Pept Res. 1991 4 : 324 33.
22. Patarroyo ME, Vinasco J, Amador R, Espejo F, Silva Y, Moreno A, Rojas M, Mora AL, Salcedo M, Valero V, Goldberg AK, Kalil J. Genetic control of the immune response to a synthetic vaccine against Plasmodium falciparum. Parasite Immunol. 1991 13 : 509 16.
23. Murillo LA, Rocha CL, Mora AL, Kalil J, Goldenberg AK, Patarroyo ME. Molecular analysis of HLA DR4-beta 1 gene in malaria vaccinees. Typing and subtyping by PCR technique and oligonucleotides. Parasite Immunol. 1991 13 : 201 10.
24. Marsh SGP, Barber LD. The HLA facts book. New York : Academic Press 2000.
25. Andersson G, Andersson L, Larhammar D, Rask L, Sigurdardottir S. Simplifying genetic locus assignment of HLA-DRB genes. Immunol Today. 1994 15 : 58 62.
26. Pico de Coana Y, Rodríguez J, Guerrero E, Barrero C, Rodriguez R, Mendoza M, Patarroyo MA. A highly infective Plasmodium vivaxstrain adapted to Aotus monkeys: quantitative haematological and molecular determinations useful for P. vivax malaria vaccine development. Vaccine. 2003 21 : 3930 7.
27. Rodriguez R, Moreno A, Guzman F, Calvo M, Patarroyo ME. Studies in owl monkeys leading to the development of a synthetic vaccine against the asexual blood stages of Plasmodium falciparum. Am J Trop Med Hyg. 1990 43 : 339 54.
28. Suarez C F, Patarroyo ME, Trujillo E, Estupinan M, Baquero JE, Parra C, Rodriguez R. Owl monkey MHC-DRB exon 2 reveals high similarity with several HLA-DRB lineages. Immunogenetics. 2006 58 : 542 58.
29. Moncada CA, Guerrero E, Cardenas P, Suarez CF, Patarroyo ME, Patarroyo MA. The T-cell receptor in primates: identifying and sequencing new owl monkey TRBV gene sub-groups. Immunogenetics. 2005 57 : 42 52.
30. Hernandez EC, Suarez CF, Mendez JA, Echeverry SJ, Murillo LA, Patarroyo ME. Identification, cloning, and sequencing of different cytokine genes in four species of owl monkey. Immunogenetics. 2002 54 : 645 53.
31. Day M. Experts back research using primates. Br Med J. 2006 333 : 1235.
32. Miller LH, Baruch DI, Marsh K, Doumbo OK. The pathogenic basis of malaria. Nature. 2002 415 : 673 9.
33. Cowman AF, Crabb BS. Invasion of red blood cells by malaria parasites. Cell. 2006 124 : 755 66.
34. Chitnis CE. Molecular insights into receptors used by malaria parasites for erythrocyte invasion. Curr Opin Hematol. 2001 8 : 85 91.
35. Rener J, Graves PM, Carter R, Williams JL, Burkot TR. Target antigens of transmission-blocking immunity on gametes of Plasmodium falciparum. J Exp Med. 1983 158 : 976 81.
36. Holder AA, Lockyer MJ, Odink KG, Sandhu JS, Riveros-Moreno V, Nicholls SC, Hillman Y, Davey LS, Tizard ML, Schwarz RT, Freeman RR. Primary structure of the precursor to the three major surface antigens of Plasmodium falciparum merozoites. Nature. 1985 317 : 270 3.
37. Marshall VM, Silva A, Foley M, Cranmer S, Wang L, McColl DJ, Kemp DJ, Coppel RL. A second merozoite surface protein (MSP-4) of Plasmodium falciparum that contains an epidermal growth factor-like domain. Infect Immun. 1997 65 : 4460 7.
38. Black CG, Wu T, Wang L, Hibbs AR, Coppel RL. Merozoite surface protein 8 of Plasmodium falciparum contains two epidermal growth factor-like domains. Mol Biochem Parasitol. 2001 114 : 217 26.
39. Gerold P, Schofield L, Blackman MJ, Holder AA, Schwarz RT. Structural analysis of the glycosyl-phosphatidylinositol membrane anchor of the merozoite surface proteins-1 and -2 of Plasmodium falciparum. Mol Biochem Parasitol. 1996 75 : 131 43.
40. Weber JL, Lyon JA, Wolff RH, Hall T, Lowell GH, Chulay JD. Primary structure of a Plasmodium falciparum malaria antigen located at the merozoite surface and within the parasitophorous vacuole. J Biol Chem. 1988 263 : 11421 5.
41. McColl DJ, Anders RF. Conservation of structural motifs and antigenic diversity in the Plasmodium falciparum merozoite surface protein-3 (MSP-3). Mol Biochem Parasitol. 1997 90 : 21 31.
42. Pachebat JA, Ling IT, Grainger M, Trucco C, Howell S, Fernandez-Reyes D, Gunaratne R, Holder AA. The 22 kDa component of the protein complex on the surface of Plasmodium falciparum merozoites is derived from a larger precursor, merozoite surface protein 7. Mol Biochem Parasitol. 2001 117 : 83 9.
43. Trucco C, Fernandez-Reyes D, Howell S, Stafford WH, Scott-Finnigan TJ, Grainger M, Ogun SA, Taylor WR, Holder AA. The merozoite surface protein 6 gene codes for a 36 kDa protein associated with the Plasmodium falciparum merozoite surface protein-1 complex. Mol Biochem Parasitol. 2001 112 : 91 101.
44. LaCount DJ, Vignali M, Chettier R, Phansalkar A, Bell R, Hesselberth JR, Schoenfeld LW, Ota I, Sahasrabudhe S, Kurschner C, Fields S, Hughes RE. A protein interaction network of the malaria parasite Plasmodium falciparum. Nature. 2005 438 : 103 7.
45. Black CG, Wang L, Wu T, Coppel RL. Apical location of a novel EGF-like domain-containing protein of Plasmodium falciparum. Mol Biochem Parasitol. 2003 127 : 59 68.
46. Adams JH, Blair PL, Kaneko O, Peterson DS. An expanding ebl family of Plasmodium falciparum. Trends Parasitol. 2001 17 : 297 9.
47. Sim BK, Orlandi PA, Haynes JD, Klotz FW, Carter JM, Camus D, Zegans ME, Chulay JD. Primary structure of the 175K Plasmodium falciparum erythrocyte binding antigen and identification of a peptide which elicits antibodies that inhibit malaria merozoite invasion. J Cell Biol. 1990 111 : 1877 84.
48. Thompson JK, Triglia T, Reed MB, Cowman AF. A novel ligand from Plasmodium falciparum that binds to a sialic acid-containing receptor on the surface of human erythrocytes. Mol Microbiol. 2001 41 : 47 58.
49. Gilberger TW, Thompson JK, Triglia T, Good RT, Duraisingh MT, Cowman AF. A novel erythrocyte binding antigen-175 par-alogue from Plasmodium falciparum defines a new trypsin-resistant receptor on human erythrocytes. J Biol Chem. 2003 278 : 14480 6.
50. Adams JH, Sim BK, Dolan SA, Fang X, Kaslow DC, Miller LH. A family of erythrocyte binding proteins of malaria parasites. Proc Natl Acad Sci USA. 1992 89 : 7085 9.
51. Rayner JC, Vargas-Serrato E, Huber CS, Galinski MR, Barnwell JW. A Plasmodium falciparum homologue of Plasmodium vivax reticulocyte binding protein (PvRBP1) defines a trypsin-resist-ant erythrocyte invasion pathway. J Exp Med. 2001 194 : 1571 81.
52. Baldi DL, Good R, Duraisingh MT, Crabb BS, Cowman AF. Identification and disruption of the gene encoding the third member of the low-molecular-mass rhoptry complex in Plasmodium falciparum. Infect Immun. 2002 70 : 5236 45.
53. Wang L, Mohandas N, Thomas A, Coppel RL. Detection of detergent-resistant membranes in asexual blood-stage parasites of Plasmodium falciparum. Mol Biochem Parasitol. 2003 130 : 149 53.
54. Sanders PR, Gilson PR, Cantin GT, Greenbaum DC, Nebl T, Carucci DJ, McConville MJ, Schofield L, Hodder AN, Yates JR, 3rd., Crabb BS. Distinct protein classes including novel merozoite surface antigens in Raft-like membranes of Plasmodium falciparum. J Biol Chem. 2005 280 : 40169 76.
55. Wang HY, Tang H, Shen CK, Wu CI. Rapidly evolving genes in human. I. The glycophorins and their possible role in evading malaria parasites. Mol Biol Evol. 2003 20 : 1795 804.
56. Duraisingh MT, Triglia T, Ralph SA, Rayner JC, Barnwell JW, McFadden GI, Cowman AF. Phenotypic variation of Plasmodium falciparum merozoite proteins directs receptor targeting for invasion of human erythrocytes. EMBO J. 2003 22 : 1047 57.
57. Duraisingh MT, Maier AG, Triglia T, Cowman AF. Erythrocyte-binding antigen 175 mediates invasion in Plasmodium falciparum utilizing sialic acid-dependent and-independent pathways. Proc Natl Acad Sci USA. 2003 100 : 4796 801.
58. Goel VK, Li X, Chen H, Liu SC, Chishti AH, Oh SS. Band 3 is a host receptor binding merozoite surface protein 1 during the Plasmodium falciparum invasion of erythrocytes. Proc Natl Acad Sci USA. 2003 100 : 5164 9.
59. Baum J, Maier AG, Good RT, Simpson KM, Cowman AF. Invasion by P. falciparum merozoites suggests a hierarchy of molecular interactions. PLoS Pathog. 2005 1 : e37.
60. Engers HD, Godal T. Malaria vaccine development: current status. Parasitol Today. 1998 14 : 56 64.
61. Graves P, Gelband H. Vaccines for preventing malaria. The Cochrane Library. 2007, Issue 3.
62. Moorthy VS, Imoukhuede EB, Milligan P, Bojang K, Keating S, Kaye P, Pinder M, Gilbert SC, Walraven G, Greenwood BM, Hill AS. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med. 2004 1 : e33.
63. Bejon P, Mwacharo J, Kai O, Mwangi T, Milligan P, Todryk S, Keating S, Lang T, Lowe B, Gikonyo C, Molyneux C, Fegan G, Gilbert SC, Peshu N, Marsh K, Hill AV. A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin Trials. 2006 1 : e29.
64. Sedegah M, Charoenvit Y, Minh L, Belmonte M, Majam VF, Abot S, Ganeshan H, Kumar S, Bacon DJ, Stowers A, Narum DL, Carucci DJ, Rogers WO. Reduced immunogenicity of DNA vaccine plasmids in mixtures. Gene Ther. 2004 11 : 448 56.
65. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Aide P, Sigauque B, Milman J, Mandomando I, Bassat Q, Guinovart C, Espasa M, Corachan S, Lievens M, Navia MM, Dubois MC, Menendez C, Dubovsky F, Cohen J, Thompson R, Ballou WR. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet. 2005 366 : 2012 8.
66. Pombo DJ, Lawrence G, Hirunpetcharat C, Rzepczyk C, Bryden M, Cloonan N, Anderson K, Mahakunkijcharoen Y, Martin LB, Wilson D, Elliott S, Elliott S, Eisen DP, Weinberg JB, Saul A, Good MF. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet. 2002 360 : 610 7.
67. Genton B, Al-Yaman F, Betuela I, Anders RF, Saul A, Baea K, Mellombo M, Taraika J, Brown GV, Pye D, Irving DO, Felger I, Beck HP, Smith TA, Alpers MP. Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. Vaccine. 2003 22 : 30 41.
68. Ockenhouse CF, Sun PF, Lanar DE, Wellde BT, Hall BT, Kester K, Stoute JA, Magill A, Krzych U, Farley L, Wirtz RA, Sadoff JC, Kaslow DC, Kumar S, Church LW, Crutcher JM, Wizel B, Hoffman S, Lalvani A, Hill AV, Tine JA, Guito K P, de Taisne C, Anders R, Horii T, Paolletti E, Ballou WR. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis. 1998 177 : 1664 73.
69. Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, Rare L, Baisor M, Lorry K, Brown GV, Pye D, Irving DO, Smith TA, Beck HP, Alpers M P. A recom-binant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis. 2002 185 : 820 7.
70. Urquiza M, Rodriguez LE, Suarez JE, Guzman F, Ocampo M, Curtidor H, Segura C, Trujillo E, Patarroyo ME. Identification of Plasmodium falciparum MSP-1 peptides able to bind to human red blood cells. Parasite Immunol. 1996 18 : 515 26.
71. Rodriguez LE, Urquiza M, Ocampo M, Suarez J, Curtidor H, Guzman F, Vargas LE, Trivinos M, Rosas M, Patarroyo ME. Plasmodium falciparum EBA-175 kDa protein peptides which bind to human red blood cells. Parasitology. 2000 120 : 225 35.
72. Vera Bravo R, Marin V, Garcia J, Urquiza M, Torres E, Trujillo M, Rosas J, Patarroyo ME. Amino terminal peptides of the ring infected erythrocyte surface antigen of Plasmodium falciparum bind specifically to erythrocytes. Vaccine. 2000 18 : 1289 93.
73. Ocampo M, Urquiza M, Guzman F, Rodriguez LE, Suarez J, Curtidor H, Rosas J, Diaz M, Patarroyo ME. Two MSA 2 peptides that bind to human red blood cells are relevant to Plasmodium falciparum merozoite invasion. J Pept Res. 2000 55 : 216 23.
74. Urquiza M, Suarez JE, Cardenas C, Lopez R, Puentes A, Chavez F, Calvo JC, Patarroyo ME. Plasmodium falciparum AMA-1 erythrocyte binding peptides implicate AMA-1 as erythrocyte binding protein. Vaccine. 2000 19 : 508 13.
75. Lopez R, Urquiza M, Curtidor H, Eduardo Caminos J, Mora H, Puentes A, Patarroyo ME. Plasmodium falciparum: red blood cell binding studies of peptides derived from histidine-rich KAHRP-I, HRP-II and HRP-III proteins. Acta Trop. 2000 75 : 349 59.
76. Puentes A, Garcia J, Vera R, Lopez QR, Urquiza M, Vanegas M, Salazar LM, Patarroyo ME. Serine repeats antigen peptides which bind specifically to red blood cells. Parasitol Int. 2000 49 : 105 17.
77. Curtidor H, Rodriguez LE, Ocampo M, Lopez R, Garcia JE, Valbuena J, Vera R, Puentes A, Vanegas M, Patarroyo ME. Specific erythrocyte binding capacity and biological activity of Plasmodium falciparum erythrocyte binding ligand 1 (EBL-1)-derived peptides. Protein Sci. 2005 14 : 464 73.
78. Ocampo M, Vera R, Rodriguez LE, Curtidor H, Suarez J, Garcia J, Puentes A, Lopez R, Valbuena J, Tovar D, Reyes C, Vega S, Patarroyo ME. Identification of Plasmodium falciparum reticulocyte binding protein RBP-2 homologue a and b (PfRBP-2-Ha and -Hb) sequences that specifically bind to erythrocytes. Parasitol Int. 2004 53 : 77 88.
79. Curtidor H, Ocampo M, Tovar D, Lopez R, Garcia J, Valbuena J, Vera R, Suarez J, Rodriguez LE, Puentes A, Guzman F, Torres E, Patarroyo ME. Specific erythrocyte binding capacity and biological activity of Plasmodium falciparum-derived rhoptry-associated protein 1 peptides. Vaccine. 2004 22 : 1054 62.
80. Curtidor H, Urquiza M, Suarez JE, Rodriguez LE, Ocampo M, Puentes A, Garcia JE, Vera R, Lopez R, Ramirez LE, Pinzon M, Patarroyo ME. Plasmodium falciparum acid basic repeat antigen (ABRA) peptides: erythrocyte binding and biological activity. Vaccine. 2001 19 : 4496 504.
81. Espejo F, Bermudez A, Torres E, Urquiza M, Rodriguez R, Lopez Y, Patarroyo ME. Shortening and modifying the 1513 MSP-1 peptide's alpha-helical region induces protection against malaria. Biochem Biophys Res Commun. 2004 315 : 418 27.
82. Espejo F, Cubillos M, Salazar LM, Guzman F, Urquiza M, Ocampo M, Silva Y, Rodriguez R, Lioy E, Patarroyo ME. Structure, immunogenicity, and protectivity relationship for the 1585 malarial peptide and its substitution analogues. Angew Chem Int Ed Engl. 2001 40 : 4654 7.
83. Cubillos M, Salazar LM, Torres L, Patarroyo ME. Protection against experimental P falciparum malaria is associated with short AMA-1 peptide analogue alpha-helical structures. Biochimie. 2002 84 : 1181 8.
84. Torres MH, Salazar LM, Vanegas M, Guzman F, Rodriguez R, Silva Y, Rosas J, Patarroyo ME. Modified merozoite surface protein-1 peptides with short alpha helical regions are associated with inducing protection against malaria. Eur J Biochem. 2003 270 : 3946 52.
85. Cifuentes G, Guzman F, Alba MP, Salazar LM, Patarroyo ME. Analysis of a Plasmodium falciparum EBA-175 peptide with high binding capacity to erythrocytes and their analogues using 1H NMR. J Struct Biol. 2003 141 : 115 21.
86. Cifuentes G, Patarroyo ME, Urquiza M, Ramirez LE, Reyes C, Rodriguez R. Distorting malaria peptide backbone structure to enable fitting into MHC class II molecules renders modified peptides immunogenic and protective. J Med Chem. 2003 46 : 2250 3.
87. Purmova J, Salazar LM, Espejo F, Torres MH, Cubillos M, Torres E, Lopez Y, Rodriguez R, Patarroyo ME. NMR structure of Plasmodium falciparum malaria peptide correlates with protective immunity. Biochim Biophys Acta. 2002 1571 : 27 33.
88. Salazar LM, Alba MP, Torres MH, Pinto M, Cortes X, Torres L, Patarroyo ME. Protection against experimental malaria associated with AMA-1 peptide analogue structures. FEBS Lett. 2002 527 : 95 100.
89. Alba MP, Salazar LM, Vargas LE, Trujillo M, López Y, Patarroyo ME. Modifying RESA protein peptide 6671 to fit into HLA-DRbeta1* pockets induces protection against malaria. Biochem Biophys Res Commun. 2004 315 : 1154 64.
90. Alba MP, Salazar LM, Puentes A, Pinto M, Torres E, Patarroyo ME. 6746 SERA peptide analogues immunogenicity and protective efficacy against malaria is associated with short alpha helix formation: malaria protection associated with peptides alpha helix shortening. Peptides. 2003 24 : 999 1006.
91. Patarroyo ME, Cifuentes G, Vargas LE, Rosas J. Structural modifications enable conserved peptides to fit into MHC mole-cules thus inducing protection against malaria. Chembiochem. 2004 5 : 1588 93.
92. Patarroyo ME, Alba MP, Vargas LE, Silva Y, Rosas J, Rodriguez R. Peptides inducing short-lived antibody responses against Plasmodium falciparum malaria have shorter structures and are read in a different MHC II functional register. Biochemistry. 2005 44 : 6745 54.
93. Patarroyo ME, Bermudez A, Salazar LM, Espejo F. High non-protective, long-lasting antibody levels in malaria are associated with haplotype shifting in MHC-peptide-TCR complex formation: a new mechanism for immune evasion. Biochimie. 2006 88 : 775 84.
94. Rammensee HG, Friede T, Stevanoviic S. MHC ligands and peptide motifs: first listing. Immunogenetics. 1995 41 : 178 228.
95. Reyes C, Patarroyo ME, Vargas LE, Rodriguez LE, Patarroyo MA. Functional, structural, and immunological compartmentalisation of malaria invasive proteins. Biochem Biophys Res Commun. 2007 354 : 363 71.
96. Blackman MJ, Holder AA. Secondary processing of the > merozoite surface protein-1 (MSP1) by a calcium-dependent membrane-bound serine protease: shedding of MSP133 as a noncovalently associated complex with other fragments of the MSP1. Mol Biochem Parasitol. 1992 50 : 307 15.
97. Pachebat JA, Kadekoppala M, Grainger M, Dluzewski AR, Gunaratne RS, Scott-Finnigan TJ, Ogun SA, Ling IT, Bannister LH, Taylor HM, Mitchell GH, Holder AA. Extensive proteolytic processing of the malaria parasite merozoite surface protein 7 during biosynthesis and parasite release from erythrocytes. Mol Biochem Parasitol. 2007 151 : 59 69.
98. Li J, Mitamura T, Fox BA, Bzik DJ, Horii T. Differential localization of processed fragments of Plasmodium falciparum serine repeat antigen and further processing of its N-terminal 47 kDa fragment. Parasitol Int. 2002 51 : 343 52.
99. Hiller NL, Bhattacharjee S, van Ooij C, Liolios K, Harrison T, Lopez-Estrano C, Haldar K. A host-targeting signal in virulence proteins reveals a secretome in malarial infection. Science. 2004 306 : 1934 7.
100. Andersen CA, Palmer AG, Brunak S, Rost B. Continuum secondary structure captures protein flexibility. Structure. 2002 10 : 175 84.
101. Hennecke J, Wiley DC. Structure of a complex of the human alpha/beta T cell receptor (TCR) HA1.7, influenza hemag-glutinin peptide, and major histocompati-bility complex class II molecule, HLA-DR4 (DRA*0101 and DRB1*0401): insight into TCR cross-restriction and alloreactivity. J Exp Med. 2002 195 : 571 81.
102. Svensson AC, Setterblad N, Pihlgren U, Rask L, Andersson G. Evolutionary relationship between human major histocompatibility complex HLA-DR haplotypes. Immunogenetics. 1996 43 : 304 14.
103. Dessen A, Lawrence CM, Cupo S, Zaller DM, Wiley DC. X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity. 1997 7 : 473 81.
104. Hennecke J, Carfi A, Wiley DC. Structure of a covalently stabilized complex of a human alphabeta T-cell receptor, influenza HA peptide and MHC class II molecule, HLA-DR1. EMBO J. 2000 19 : 5611 24.
105. Reinherz EL, Tan K, Tang L, Kern P, Liu J, Xiong Y, Hussey RE, Smolyar A, Hare B, Zhang R, Joachimiak A, Chang HC, Wagner G, Wang J. The crystal structure of a T cell receptor in complex with peptide and MHC class II. Science. 1999 286 : 1913 21.
106. Jones EY, Fugger L, Strominger JL, Siebold C. MHC class II proteins and disease: a structural perspective. Nat Rev Immunol. 2006 6 : 271 82.
107. Cardenas C, Villaveces JL, Bohorquez H, Llanos E, Suarez C, Obregon M, Patarroyo ME. Quantum chemical analysis explains hemagglutinin peptide-MHC Class II molecule HLA-DRbeta1*0101 interactions. Biochem Biophys Res Commun. 2004 323 : 1265 77.
108. Cardenas C, Villaveces JL, Suarez C, Obregon M, Ortiz M, Patarroyo ME. A comparative study of MHC Class-II HLA-DRbeta1*0401-Col II and HLA-DRbeta1*0101-HA complexes: a theoretical point of view. J Struct Biol. 2005 149 : 38 52.
109. Bermudez A, Cifuentes G, Guzman F, Salazar LM, Patarroyo ME. Immunogeni-city and protectivity of Plasmodium falciparum EBA-175 peptide and its analog is associated with alpha-helical region shortening and displacement. Biol Chem. 2003 384 : 1443 50.